Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

The U.S. Food and Drug Administration accepted Novartis’ Biologics License Application and granted Priority Review for the company’s investigational sickle cell medicine crizanlizumab (SEG101).

Read More »

Global Blood Therapeutics’ Sickle Cell Disease Drug Hits the Mark in Phase III Trial

Global Blood Therapeutics reported new data from the company’s Phase III HOPE trial of voxelotor in sickle cell disease (SCD).

Read More »

BioMarin’s Hemophilia A Gene Therapy Shows Promise in Clinical Trial

San Rafael, Calif.-based BioMarin Pharmaceutical announced positive Phase III clinical trial results for the company’s gene therapy, valoctocogene roxaparvovec, for adults with hemophilia A.

Read More »

Myovant Sciences’ uterine fibroids combo therapy meets main goal in study

Myovant Sciences’ combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids.

Read More »

Bayer to Invest $150 Million in New Cell Manufacturing Plant in Berkeley

Bayer plans to build a Cell Culture Technology Center in Berkeley, Calif., investing $150 million in the project. The center will focus on developing biologics, an area where Bayer lags behind the company’s competitors.

Read More »

Bayer looking into established drugs strategy

Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.

Read More »

Exclusive: Astellas’ Xospata Provides Strong OS Benefits in Phase III Trial

Astellas Pharma’s blood cancer drug Xospata continues to show impressive results in the acute myeloid leukemia setting.

Read More »

EMA panel recommends approval of Bluebird Bio’s first gene therapy

A European Medicines Agency panel recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc. as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win the company’s first regulatory nod.

Read More »

Agios Receives FDA Breakthrough Therapy Designation for Tibsovo-Azacitidine Combination for AML

Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation for Tibsovo (ivosidenib) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Read More »

Pfizer buys stake in French gene therapy firm Vivet

Pfizer acquired a 15 percent stake in Vivet Therapeutics as well as an exclusive option to fully acquire the business, a deal that will give the New York-based pharma giant access to the French company’s experimental gene therapy for a rare genetic disorder.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom